Aquabounty Technologies (AQB) Stock
Biotech company developing faster growing Atlantic salmon. Here's the price, business snapshot, and what's worth knowing about Aquabounty Technologies in August 2026.
Aquabounty Technologies Inc (AQB) is a micro‑cap biotechnology company that develops faster‑growing Atlantic salmon through its AquAdvantage genetic line. The commercial idea is to reduce time to market and production costs for farmed salmon, potentially improving the economics of aquaculture. With a market capitalisation around $6.28 million, AQB is small and highly speculative: shares can be volatile and liquidity is limited. The company has a notable regulatory history — including past FDA reviews — but commercial rollout has been slow and has faced operational, consumer‑acceptance and supply‑chain challenges. Potential upside exists if production scales, acceptance improves and sales grow, but risks include financing needs, regulatory changes, reputational concerns and operational setbacks. This information is educational only and not personal financial advice. Investors should carry out their own research, consider their risk tolerance and suitability, and be aware that values can rise or fall and returns are not guaranteed.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest selling Aquabounty Technologies stock as its target price is below its current value.
Financial Health
Aquabounty Technologies shows moderate financial performance with steady cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Growth Efficiency Case
AquAdvantage salmon aims to reach market size faster, which could lower unit costs if scaled; however, commercial adoption and economics remain uncertain.
Sustainable Aquaculture
Genetic improvements may support more efficient farming and reduced resource use, though consumer acceptance and regulation could limit market access.
Regulatory Watch
Past regulatory milestones matter for sales and exports; any future approvals or restrictions will materially affect prospects, and the small market cap adds risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
